Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation

Biochemical and Biophysical Research Communications

Volumn 385, Issue 2, 2009, Pages 269-272

  Matsui, Takanori ^a   Yamagishi, Sho ichi ^a   Takeuchi, Masayoshi ^b   Ueda, Seiji ^a   Fukami, Kei ^a   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

AGE; Diabetic nephropathy; Nifedipine; PPAR ; RAGE

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMLODIPINE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NIFEDIPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DAMAGE; CELL PROTECTION; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; MESANGIUM CELL; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; TRANSCRIPTION REGULATION;

ANILIDES; CALCIUM CHANNEL BLOCKERS; CHEMOKINE CCL2; CYTOPROTECTION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MESANGIAL CELLS; NIFEDIPINE; PPAR GAMMA; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC; TRANSCRIPTION, GENETIC;

EID: 67349131842     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.05.061     Document Type: Article

References (12)

1. Yamagishi S., Fukami K., Ueda S., and Okuda S. Molecular mechanisms of diabetic nephropathy, its therapeutic intervention. Curr. Drug Targets 8 (2007) 952-959
2. Yamagishi S., and Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des. 11 (2005) 2279-2299
3. Yamagishi S., Matsui T., and Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr. Drug Targets 8 (2007) 1138-1143
4. Mancia G. Optimal control of blood pressure in patients with diabetes reduces the incidence of macro, microvascular events. J. Hypertens. Suppl. 1 (2007) S7-S12
5. Yamagishi S., Nakamura K., and Matsui T. Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. Curr. Med. Chem. 15 (2008) 172-177
6. Yamagishi S., Nakamura K., Matsui T., Inagaki Y., Takenaka K., Jinnouchi Y., Yoshida Y., Matsuura T., Narama I., Motomiya Y., Takeuchi M., Inoue H., Yoshimura A., Bucala R., and Imaizumi T. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J. Biol. Chem. 281 (2006) 20213-20220
7. Wang F., Li M., Cheng L., Zhang T., Hu J., Cao M., Zhao J., Guo R., Gao L., and Zhang X. Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats. Life Sci. 83 (2008) 828-835
8. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., Rollin B.J., and Tesch G.H. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 69 2006 (2006) 73-80
9. Baba S. J-MIND study group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diab. Res. Clin. Prac. 54 (2001) 191-201
10. Marx N., Walcher D., Ivanova N., Rautzenberg K., Jung A., Friedl R., Hombach V., de Caterina R., Basta G., Wautier M.P., and Wautiers J.L. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 53 (2004) 2662-2668
11. Takeuchi M., Makita Z., Yanagisawa K., Kameda K., and Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol. Med. 5 (1999) 393-405
12. Yoshida T., Yamagishi S., Nakamura K., Matsui T., Imaizumi T., Takeuchi M., Koga H., Ueno T., and Sata M. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 49 (2006) 3094-3099